Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Metastasis Impact on Survival in Gefitinib-Treated NSCLC
NCT03157310Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2009
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Overall Survival at 5 years. Started May 2009; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03157310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157310.